Researchers have achieved a significant breakthrough in the fight against skin cancer, aiming to potentially save numerous lives annually.
The discovery reveals that a small molecule, typically involved in gene regulation, is also responsible for promoting the growth of lethal cancer by enabling tumors to avoid attacks from the immune system. The identified gene, HOXD13, plays a crucial role in fueling melanoma development and inhibiting the necessary T cell response to combat the cancer, facilitating its spread to other body parts.
Skin cancer claims around 2,500 lives each year in the UK and over 8,000 in the US. However, scientists are optimistic about creating inhibitor medications that target melanoma at a molecular level.
Pietro Berico, the lead investigator of the study and a postdoctoral research fellow at New York University’s Grossman School of Medicine and Perlmutter Cancer Centre, emphasized the significance of HOXD13 in driving melanoma growth and suppressing T cell activity crucial for fighting the disease.
Dr. Hernando-Monge, a professor in the Department of Pathology and a senior researcher in the study, mentioned ongoing clinical trials evaluating the safety, dosage tolerance, and efficacy of inhibitor drugs against melanoma and other cancers. Some trials combine inhibitors with existing immunotherapy to harness the immune system’s power against cancer.
“This data supports the combined targeting of angiogenesis and adenosine-receptor pathways as a promising new treatment approach for HOXD13-driven melanoma,” she added. Researchers conducted a thorough analysis of tumors from over 200 melanoma patients in the US, Brazil, and Mexico to identify elevated or suppressed genetic pathways, with HOXD13 emerging as a significant factor.
Further investigations in mice and human melanoma cell lines demonstrated that HOXD13 promotes angiogenesis and immune system evasion. Inhibition tests involving HOXD13, VEGF, and adenosine highlighted HOXD13’s critical role in the cancer’s growth and survival.
Melanoma skin cancer typically manifests as a new mole or a changing existing mole in terms of size, shape, or color. Warning signs include moles with irregular edges, multiple colors, itchiness, inflammation, or bleeding, prompting individuals to consult a GP if they notice any unusual skin spots.
In the UK, approximately 90% of skin cancer cases are non-melanoma, predominantly caused by exposure to ultraviolet light, leading to basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) as the primary types.
